Abstract
Importance: Effective treatments for patients with severe COVID-19 are needed.
Objective: To evaluate the efficacy of canakinumab, an anti-interleukin-1β antibody, in patients hospitalized with severe COVID-19.
Design, setting, and participants: This randomized, double-blind, placebo-controlled phase 3 trial was conducted at 39 hospitals in Europe and the United States. A total of 454 hospitalized patients with COVID-19 pneumonia, hypoxia (not requiring invasive mechanical ventilation [IMV]), and systemic hyperinflammation defined by increased blood concentrations of C-reactive protein or ferritin were enrolled between April 30 and August 17, 2020, with the last assessment of the primary end point on September 22, 2020.
Intervention: Patients were randomly assigned 1:1 to receive a single intravenous infusion of canakinumab (450 mg for body weight of 40-<60 kg, 600 mg for 60-80 kg, and 750 mg for >80 kg; n = 227) or placebo (n = 227).
Main outcomes and measures: The primary outcome was survival without IMV from day 3 to day 29. Secondary outcomes were COVID-19-related mortality, measurements of biomarkers of systemic hyperinflammation, and safety evaluations.
Results: Among 454 patients who were randomized (median age, 59 years; 187 women [41.2%]), 417 (91.9%) completed day 29 of the trial. Between days 3 and 29, 198 of 223 patients (88.8%) survived without requiring IMV in the canakinumab group and 191 of 223 (85.7%) in the placebo group, with a rate difference of 3.1% (95% CI, -3.1% to 9.3%) and an odds ratio of 1.39 (95% CI, 0.76 to 2.54; P = .29). COVID-19-related mortality occurred in 11 of 223 patients (4.9%) in the canakinumab group vs 16 of 222 (7.2%) in the placebo group, with a rate difference of -2.3% (95% CI, -6.7% to 2.2%) and an odds ratio of 0.67 (95% CI, 0.30 to 1.50). Serious adverse events were observed in 36 of 225 patients (16%) treated with canakinumab vs 46 of 223 (20.6%) who received placebo.
Conclusions and relevance: Among patients hospitalized with severe COVID-19, treatment with canakinumab, compared with placebo, did not significantly increase the likelihood of survival without IMV at day 29.
Trial registration: ClinicalTrials.gov Identifier: NCT04362813 .
【초록키워드】 Treatment, Efficacy, Europe, Biomarker, Mortality, Trial, severe COVID-19, hypoxia, Pneumonia, antibody, hospital, C-reactive protein, ferritin, outcome, Randomized, survival, phase 3 trial, adverse event, Patient, Placebo, women, placebo-controlled, Blood, Invasive mechanical ventilation, Concentration, Odds ratio, double-blind, Primary outcome, 95% CI, median age, primary end point, single intravenous infusion, systemic hyperinflammation, The United States, IMV, secondary, likelihood, Randomly, enrolled, defined, evaluate, occurred, significantly, conducted, treated, hospitalized patient, assigned, survived, receive, 1:1, patients hospitalized, the placebo group, with COVID-19, 【제목키워드】 clinical, canakinumab, Effect, Mechanical,